Androgen receptor: A new player in triple negative breast cancer management

Mehta, Anurag; Dogra, Atika

doi:10.4103/jco.jco_41_20

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Women with AR-positive TNBC reportedly had considerably better disease-free survival (DFS) and better overall survival (OS), according to Thike et al These tumors also have a lower chance of recurrence, in contrast to ARnegative tumors, which are more likely to metastasize and reoccur [61]. On the other hand, some studies have suggested that AR expression is associated with higher mortality rates in patients with TNBC [14].…”

Section: The Biological Role Of Androgen Receptormentioning

confidence: 99%

“…Androgens activate the AR and render positive or negative genetic regulations. Mutations that occur during these regulatory mechanisms threaten the occurrence of carcinogenesis [14]. The notable contribution of androgen-mediated growth stimulation and AR expression laid the foundation for androgen receptor antagonists as avant-gardes in the mitigation of LAR-associated TNBC [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

Khadela

Chavda

Soni

et al. 2022

Cancers

View full text Add to dashboard Cite

Triple-negative tumors are progressively delineating their existence over the extended spectrum of breast cancers, marked by intricate molecular heterogeneity, a low overall survival rate, and an unexplored therapeutic approach. Although the basal subtype transcends the group and contributes approximately 80% to triple-negative breast cancer (TNBC) cases, the exceptionally appearing mesenchymal and luminal androgen receptor (LAR) subtypes portray an unfathomable clinical course. LAR with a distinct generic profile frequently metastasizes to regional lymph nodes and bones. This subtype is minimally affected by chemotherapy and shows the lowest pathologic complete response. The androgen receptor is the only sex steroid receptor that plays a cardinal role in the progression of breast cancers and is typically overexpressed in LAR. The partial AR antagonist bicalutamide and the next-generation AR inhibitor enzalutamide are being assessed in standard protocols for the mitigation of TNBC. There arises an inevitable need to probe into the strategies that could neutralize these androgen receptors and alleviate the trajectory of concerning cancer. This paper thus focuses on reviewing literature that provides insights into the anti-androgenic elements against LAR typical TNBC that could pave the way for clinical advancements in this dynamic sphere of oncology.

show abstract

Section: The Biological Role Of Androgen Receptormentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%